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Abstract
Introduction This post-authorization safety study (PASS) was a commitment to the European Medicines Agency.
Objective This PASS investigated quetiapine as antidepressant treatment in Swedish registers with regard to the risk for 
all-cause mortality, self-harm and suicide, acute myocardial infarction, stroke, diabetes mellitus, extrapyramidal disorders, 
and somnolence.
Methods Users of quetiapine and antidepressants (2011‒2014) who had changed treatment in the past year were included. 
Conditional logistic regression models were used to calculate odds ratios (ORs) and their 95% confidence intervals (CIs) 
for each outcome in nested case–control studies for quetiapine as combination therapy and monotherapy, monotherapy with 
antidepressants, and no medication, versus the use of combinations of antidepressants (reference group).
Results Overall, 7421 quetiapine users and 281,303 antidepressant users were included. For quetiapine in combination, 
risks were increased for all-cause mortality [adjusted OR (aOR) 1.31, 95% CI 1.12–1.54] compared with combinations of 
antidepressants; however, when stratified by age, only patients ≥ 65 years of age had an increased mortality, and, in a post 
hoc analysis excluding patients with Parkinson’s disease, no mortality increase remained. Furthermore, the risk for self-
harm and suicide was increased (aOR 1.53, 95% CI 1.31–1.79), but when stratified by age, the risk increase was found only 
among patients aged 18–64 years. Risks were also increased for stroke among patients ≥ 65 years of age (aOR 1.47, 95% CI 
1.01–2.12), for extrapyramidal disorder (aOR 6.15, 95% CI 3.57–10.58), and for somnolence (aOR 2.41, 95% CI 1.42–4.11).
Conclusion Risks for all-cause mortality, self-harm and suicide, and stroke in older patients may be higher among patients 
treated with quetiapine and antidepressant combination therapy.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4026 4-019-00889 -0) contains 
supplementary material, which is available to authorized users.
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1 Introduction
Major depressive disorder (MDD) is an often disabling 
psychiatric condition that is characterized by one or more 
discrete depressive episodes of at least 2 weeks’ duration 
involving changes in affect, cognition, and vegetative symp-
toms [1]. It affects about 6% of the population globally and 
occurs twice as often in women than in men [1–3]. Globally, 
MDD is the leading mental disorder associated with suicide 
and is also the second highest disease burden on society 
in terms of its treatment costs and effect on families and 
careers [4, 5].
More than 30% of patients with MDD do not achieve 
remission after the first two treatment trials [6, 7]. Several 
studies of add-on treatment with atypical antipsychotics, 
such as olanzapine, risperidone, quetiapine, and aripipra-
zole, have shown superior effects compared with placebo 
in patients with treatment-resistant MDD [8–10]. This has 
led to recommendations in clinical guidelines for the addi-
tion of certain atypical antipsychotics to antidepressants as 
second-line treatment in MDD [11]; however, in Sweden, 
quetiapine is the only atypical antipsychotic indicated for 
the treatment of MDD.
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Key Points 
In this post-authorization safety study, quetiapine com-
bination therapy compared with antidepressant combi-
nation therapy was associated with an elevated risk for 
all-cause mortality and stroke among patients aged ≥ 65 
years, and for self-harm and suicide among patients aged 
18–64 years.
Patients treated with quetiapine compared with antide-
pressants had a higher burden of disease and comorbidi-
ties, and a greater degree of alcohol abuse, substance 
abuse, anxiolytic and hypnotic use, suggesting selective 
prescribing to patients with a higher baseline risk profile.
No increased risks were observed for acute myocar-
dial infarction and diabetes, and, in a post hoc analysis 
excluding patients with Parkinson’s disease, no increased 
mortality in quetiapine-treated patients remained.
Quetiapine is an atypical dibenzothiazepine antipsychotic 
drug with antagonistic activity on dopamine, serotonin, his-
tamine, and adrenergic receptors [12]. The extended-release 
(XR) formulation of quetiapine has demonstrated efficacy 
and safety compared with placebo in the treatment of MDD, 
both as monotherapy and as an add-on therapy to antidepres-
sants [13, 14]. This formulation was approved as an add-on 
treatment for MDD by the European Medicines Agency in 
2010 and the US FDA in 2009 [15, 16].
Clinical studies in patients with MDD reported that the 
most common adverse events (AEs) associated with quetia-
pine, either as monotherapy or as an add-on to antidepres-
sants, were dry mouth, sedation, somnolence, headache, 
dizziness, weight gain, hyperlipidemia, hyperglycemia, and 
extrapyramidal effects [13, 14, 17]. In patients with schizo-
phrenia, an elevated risk for cardiovascular mortality has 
been observed with high exposure to typical and atypical 
antipsychotics, including quetiapine, compared with low or 
moderate exposure [18, 19]. Among patients with bipolar 
disorder, the risk for developing diabetes was found to be 
elevated in quetiapine users compared with users of con-
ventional antipsychotics [20]. However, the risk profile of 
patients with psychotic disorders may differ from that of 
other patients prescribed quetiapine, since many patients 
with psychotic disorders already have markedly elevated car-
diometabolic risk factors at treatment baseline [21]. The AE 
profile of quetiapine when used as an antipsychotic or mood-
stabilizing agent is well established, although the potential 
risks for the population of patients receiving quetiapine as an 
add-on to antidepressants may differ. This could be because 
of differing patient characteristics and possible differing 
pharmacological actions from quetiapine both in single-use 
and in combination. Moreover, while some AEs may be of 
an acute nature, e.g. akathisia, others may be related to long-
term exposure, e.g. metabolic effects.
As part of a program of post-authorization safety stud-
ies in European databases to support the XR formulation 
of quetiapine in MDD, the aim of this study was to inves-
tigate the safety of quetiapine use in Sweden with regard 
to the risk for all-cause mortality, acute myocardial infarc-
tion (AMI), stroke, self-harm and suicide, diabetes mellitus, 
extrapyramidal disorders, and somnolence among patients 
prescribed quetiapine as an add-on treatment to antidepres-
sants, compared with patients prescribed combinations of 
antidepressants.
2  Methods
2.1  Data Sources
In this retrospective, population-based study, patients were 
identified in the Prescribed Drug Register (PDR), which 
contains data on all prescriptions dispensed in retail phar-
macies in Sweden from 1 July 2005 [22]. Linked patient 
data from three other Swedish registers were obtained, 
using the unique personal identification number assigned 
to all Swedish residents [23]: the National Patient Register 
(NPR), which contains diagnoses registered at all in- and 
outpatient specialized healthcare settings, as well as data on 
age, sex, and place of residence [24]; the Total Population 
Register, which contains information on dates of emigration 
and deaths for all residents in Sweden [25]; and the Cause 
of Death Register (CDR), which contains information on all 
deaths in Sweden, including main and contributory causes 
of death, based on death certificates [26].
2.2  Study Population
Patients aged ≥ 18 years at study entry who had a prescrip-
tion filling for an antidepressant (AD) [excluding bupro-
pion under the brand name of Zyban (GlaxoSmithKline 
AB, Solna, Sweden), prescribed for smoking cessation], or 
quetiapine, in 2011–2014, were identified from the PDR. Of 
these, patients who had a prescription filling for a different 
antidepressant in the last year (including fillings from 2010 
for the earliest patients)—indicating a treatment change—
were included in the study. The date of study entry (index 
date) was the date of the first treatment change (index dis-
pensing, i.e. either add-on treatment or treatment switch). 
Patients who were not residing in Sweden in the year prior 
to study entry, who had a diagnosis [International Classi-
fication of Diseases, Tenth Revision (ICD-10)] of demen-
tia or psychotic or bipolar disorder from 1 January 1997 
to the index dispensing, who had been dispensed a mood 
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stabilizer (defined as lithium, carbamazepine, lamotrigine, 
or valproate) from 1 July 2005 to the index dispensing, and 
who had been dispensed any antipsychotic (excluding lith-
ium) in the year prior to study entry were excluded from the 
study. Patients who experienced any event from the exclu-
sion criteria during follow-up were censored on the date of 
the event, as were those who experienced 365 days without a 
prescription filling of any antidepressant or quetiapine. Thus, 
a dynamic study population was created so that each patient 
could contribute to multiple episodes of drug use by enter-
ing the population when the eligibility criteria were fulfilled 
and leaving the population when a new prescription filling 
had not occurred in 365 days. Patients were followed until 
study end (31 December 2014) or the first occurrence of a 
censoring event, emigration, or death. Figure 1 summarizes 
the study population selection.
2.3  Cases and Controls
The safety outcomes included in the study were (1) all-
cause mortality, identified by the date of death in the CDR; 
(2) AMI, defined as ICD-10 code I21; (3) stroke (ICD-10, 
I60–I69); (4) diabetes mellitus {ICD-10, E11, E13–E14, 
and/or prescription filling of any antidiabetic drug [anatomi-
cal therapeutic chemical (ATC) A10 antidiabetics)}; (5) self-
harm and suicide (ICD-10: X60–X84, intentional self-harm; 
and Y10–Y34, events of undetermined intent); (6) extrapy-
ramidal disorder [ICD-10: G21, secondary parkinsonism; 
G24, drug-induced dystonia, and/or prescription filling 
of trihexyphenidyl (ATC N04AA01) and biperiden (ATC 
N04AA02)]; and (7) somnolence (ICD-10, R40). In order 
to include incident outcome events only, patients with prior 
diagnoses or prescriptions for the outcomes were excluded 
from analyses, except for the self-harm and suicide outcome, 
where analyses were performed both on all patients and on 
patients without prior diagnoses of self-harm or suicidal 
behavior. Patients having any of the above outcomes were 
defined as cases.
Up to five controls were individually matched to each 
case, using incidence density sampling, with the match-
ing criteria being age (± 5 years), sex, and calendar year of 
study entry. To be selected as a control, a patient had to be 
included in the study population and free of the outcome in 
question at the time the outcome occurred in the case. Cases 
hospitalized for more than 30 days immediately prior to a 
death identified in the CDR were excluded, along with their 
Fig. 1  Flow of study popula-
tion. IR immediate release, XR 
extended release
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controls, since medications given during hospitalization 
were not recorded in the PDR and were therefore unknown.
2.4  Exposures
The exposure to current pharmacologic treatment at the time 
of the outcome event was estimated according to the data on 
prescription filling, package size, and prescription dosage 
instructions from the PDR. Exposures were categorized as 
(1) quetiapine monotherapy; (2) combination therapy with 
quetiapine; (3) monotherapy with antidepressants; (4) no 
medication; and (5) users of antidepressants as combination 
therapy, which was set as the reference group.
2.5  Statistical Analyses
Conditional logistic regression models were used to estimate 
crude and adjusted odds ratios (aORs) and their 95% confi-
dence intervals (CIs), to compare occurrence of the exposure 
between cases and controls for each of the seven outcomes. 
Because of the case-control design with incidence density 
sampling, the resulting odds ratios may be interpreted as 
relative risks (incidence rate ratios).
The analyses were adjusted for potential confounders that 
included comorbidities or comedications. The adjustments 
were performed with a predefined set of covariate variables 
for each outcome, and confounders were included in the 
analyses according to prespecified priorities [Table S1 of 
the electronic supplementary material (ESM)].
Two additional potential confounders were adjusted for in 
post hoc analyses: (1) severity of psychiatric illness meas-
ured as the number of hospital admissions for MDD in the 
past year and since 1997; and (2) severity of non-psychiatric 
illness measured as the number of hospital admissions for 
non-psychiatric conditions. Sensitivity analyses for selected 
outcomes were performed on patients stratified by age at 
outcome event: 18–64 years and ≥ 65 years. A post hoc 
analysis for all-cause mortality was performed by excluding 
patients with a diagnosis of Parkinson’s disease or parkin-
sonism (ICD-10 G20, G21.9, G23.1, G23.8, G31.8) or those 
who were taking medication for Parkinson’s disease (ATC 
N04) before the index date. A post hoc analysis for the self-
harm and suicide outcome was performed on patients strati-
fied by age groups: < 25 years, 25–39 years, 40–64 years, 
and ≥ 65 years.
Using a time-dependent exposure analysis (nested 
case–control study approach), data for medication at the date 
of an outcome are presented. An additional analysis was 
performed that included an intention-to-treat analysis (his-
torical prospective cohort approach) for outcomes described 
on the basis of index medication (details available from the 
corresponding author).
All analyses were performed using  SAS® version 9.4 
(SAS Institute, Cary, NC, USA).
3  Results
3.1  Patient Characteristics of the Overall Study 
Population
Of 1,514,368 new users of antidepressants or quetiapine, the 
number fulfilling inclusion criteria and initiating treatment 
with quetiapine was 7421 (58.2% women), and 281,303 
(66.5% women) for those initiating treatment with antide-
pressants (Fig. 1). Characteristics of the overall study popu-
lation and the case–control sets are shown in Table 1. The 
mean age was lower for quetiapine users than antidepressant 
users (43 vs. 51 years).
A higher proportion of quetiapine users compared with 
antidepressant users had a history of alcohol and other 
substance-use disorder, a history of self-harm, a psychiatric 
diagnosis in specialized care, a diagnosis of MDD, a diag-
nosis of psychiatric disorders other than MDD, prescriptions 
written in specialized psychiatric care settings, and one or 
more hospitalizations, including an MDD diagnosis in the 
year prior to the index date (data not shown). Similar propor-
tions of quetiapine users and antidepressant users had one 
or more hospitalizations for a non-psychiatric illness in the 
year prior to the index date and had prescriptions written 
in non-psychiatric care and other clinic settings (data not 
shown). A markedly lower proportion of prescriptions for 
quetiapine than for antidepressants were written in primary 
care settings (data not shown).
3.2  All‑Cause Mortality
The risk of all-cause mortality was higher for current use of 
combination therapy with quetiapine and an antidepressant 
(aOR 1.31, 95% CI 1.12–1.54), but not for quetiapine mono-
therapy, compared with combination therapy with more than 
one antidepressant (Table 2). When stratified by age, the all-
cause mortality was elevated only among patients ≥ 65 years 
of age (aOR 1.31, 95% CI 1.09–1.58) (Table 3). In a post hoc 
analysis excluding the 252 patients (71 cases, 181 controls) 
aged < 65 years with a diagnosis of Parkinson’s disease or 
those who were taking medication for Parkinson’s disease, 
no risk increase was seen among patients with quetiapine 
in combination therapy or monotherapy in either age group 
(18‒64 years and ≥ 65 years) (Table S2 of the ESM).
3.3  AMI, Stroke, and Diabetes
No increased risk of AMI, stroke, or diabetes was observed 
for combination therapy or monotherapy use of quetiapine 
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compared with combination therapy with antidepressants 
(Table 2). However, when stratified by age, a higher risk 
for stroke was identified (aOR 1.47, 95% CI 1.01–2.12) 
with combination therapy with quetiapine in the older 
(≥ 65  years) age group (Table  3). An additional, post 
hoc analysis showed ORs that were somewhat higher for 
ischemic stroke than for stroke due to bleeding, with a sta-
tistically higher risk for ischemic stroke in users of combina-
tion therapy with quetiapine and users of monotherapy with 
AD (Table S3 of the ESM).
3.4  Self‑Harm and Suicide
The risk was higher for self-harm and suicide among current 
users of combination therapy with quetiapine (aOR 1.53, 
95% CI 1.31–1.79) compared with combination therapy 
with antidepressants (Table 2). The risk was also elevated 
among patients without a prior history of self-harm (aOR 
1.52, 95% CI 1.26–1.84). When stratified by age group, the 
risk was increased for monotherapy or combination therapy 
with quetiapine in the 18–64 years age group only (Table 3).
3.5  Extrapyramidal Disorder and Somnolence
The risks were higher for extrapyramidal disorder (aOR 
6.15, 95% CI 3.57–10.58) and somnolence (aOR 2.41, 95% 
CI 1.42–4.11) among current users of combination therapy 
with quetiapine compared with combination therapy with 
antidepressants; however, numbers were small in most 
groups (Table 2).
4  Discussion
In this study, patients with second-line combination 
therapy of quetiapine with antidepressants were found to 
have an increased risk for all-cause mortality and stroke 
(if ≥ 65 years of age), suicide and self-harm, extrapyramidal 
disorder, and somnolence compared with patients with com-
binations of antidepressants. In general, patients prescribed 
quetiapine had differing characteristics before study entry 
regarding various aspects of psychiatric morbidity compared 
with those prescribed antidepressants. This suggests that 
results could be interpreted considering the phenomenon of 
‘channeling’, (i.e. selective prescribing in populations who 
do not adequately respond to earlier approved drugs and/or 
do not tolerate them) [27–29].
4.1  All‑Cause Mortality
Use of atypical antipsychotics, including quetiapine, has 
been associated with an increased mortality risk compared 
with psychiatric non-users [30]. While all-cause mortality 
was associated with quetiapine in combination with antide-
pressants in the present study among patients aged 65 years 
and above, the association did not remain in the post hoc 
analysis that excluded patients with Parkinson’s disease. 
Hence, the risk increase may be due to the known increased 
mortality associated with Parkinson’s disease [31]. Antipsy-
chotic use has also been associated with a doubled mortal-
ity risk among patients with Parkinson’s disease in a retro-
spective study in which quetiapine was the most commonly 
prescribed atypical antipsychotic, with an associated hazard 
ratio for death of 2.16 [32]. In the present study, a substan-
tial number of patients aged > 65 years using quetiapine 
had a diagnosis of, or had been prescribed medication for, 
Parkinson’s disease prior to the index date compared with 
those treated with antidepressants (40% vs. 6%). It is unclear 
whether these patients were prescribed quetiapine for MDD, 
a common comorbidity in patients with Parkinson’s disease, 
or for psychotic symptoms associated with Parkinson’s dis-
ease. Although not licensed for this purpose, quetiapine is 
recommended in several guidelines as a treatment for psy-
chotic symptoms in Parkinson’s disease [33–35]. However, 
the results from this study support the notion that quetiapine 
should be used with caution in elderly patients with Parkin-
son’s disease, regardless of the reason for treatment.
4.2  Self‑Harm and Suicide
Quetiapine in combination with antidepressants was associ-
ated with an increased risk for self-harm and suicide when 
compared with the use of combinations of antidepressants, 
both among patients with and without a history of self-
harm. This is in contrast to a previous study where add-on 
use of quetiapine was shown to decrease suicidality among 
patients with unipolar depression [36]. A pooled analysis of 
randomized clinical trials in patients with MDD reported 
no increased incidence of treatment-emergent suicidality in 
patients treated with quetiapine who were not already con-
sidered to be at high suicide risk at baseline [37]. In the 
present study, one could speculate that the association seen 
may be due to confounding by higher rates of psychiatric 
morbidity among patients prescribed quetiapine compared 
with those prescribed antidepressants, including a history of 
psychiatric diagnosis, alcohol abuse, substance abuse, and 
anxiolytic and hypnotic use, which we may not have been 
able to fully control for. Of special consideration may be a 
reported off-label use of quetiapine in patients with border-
line personality disorder, a patient group with high rates of 
self-harm and suicide attempts [38].
4.3  AMI, Stroke, and Diabetes
Quetiapine, as well as many other psychotropic drugs, 
has been associated with an increased risk for metabolic 
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Table 2  Case–control analysis for the association between study outcomes and treatment with quetiapine or ADs at the time of an event
Adjusted ORs and their 95% CIs were estimated with conditional logistic regression models, including all prespecified covariates, using combi-
nation therapy with ADs as the reference category
AD antidepressant, AMI acute myocardial infarction, CI confidence interval, OR odds ratio, Ref reference
a Excluding patients with a history of self-harm prior to the index date
Cases [n (%)] Controls [n (%)] Conditional logistic regression
Crude OR (95% CI) Adjusted OR (95% CI)
All-cause mortality
Combination therapy with quetiapine 231 (1.8) 853 (1.3) 1.23 (1.06–1.43) 1.31 (1.12–1.54)
Monotherapy with quetiapine 56 (0.4) 195 (0.3) 1.30 (0.96–1.76) 1.37 (0.99–1.89)
Combination therapy with ADs 4637 (35.3) 21,041 (32.1) 1 (Ref) 1 (Ref)
Monotherapy with AD 6078 (46.3) 32,672 (49.8) 0.84 (0.80–0.88) 0.88 (0.84–0.92)
No AD 2124 (16.2) 10,864 (16.6) 0.88 (0.83–0.93) 0.96 (0.90–1.02)
AMI
Combination therapy with quetiapine 29 (1.4) 139 (1.4) 0.99 (0.65–1.48) 0.98 (0.64–1.51)
Monotherapy with quetiapine 6 (0.3) 27 (0.3) 1.05 (0.43–2.54) 1.31 (0.54–3.20)
Combination therapy with ADs 632 (31.3) 2983 (29.6) 1 (Ref) 1 (Ref)
Monotherapy with AD 980 (48.6) 5139 (50.9) 0.90 (0.80–1.00) 0.93 (0.83–1.05)
No AD 371 (18.4) 1802 (17.9) 0.97 (0.84–1.12) 1.01 (0.87–1.18)
Stroke
Combination therapy with quetiapine 51 (1.8) 190 (1.3) 1.23 (0.89–1.68) 1.26 (0.91–1.74)
Monotherapy with quetiapine 10 (0.3) 43 (0.3) 1.07 (0.53–2.14) 1.21 (0.60–2.45)
Combination therapy with ADs 946 (32.5) 4338 (29.8) 1 (Ref) 1 (Ref)
Monotherapy with AD 1419 (48.7) 7405 (50.8) 0.87 (0.80–0.96) 0.89 (0.81–0.98)
No medication 487 (16.7) 2589 (17.8) 0.85 (0.75–0.97) 0.90 (0.80–1.02)
Diabetes mellitus
Combination therapy with quetiapine 46 (1.6) 221 (1.5) 0.86 (0.62–1.19) 0.87 (0.62–1.22)
Monotherapy with quetiapine 11 (0.4) 54 (0.4) 0.84 (0.44–1.61) 0.86 (0.45–1.66)
Combination therapy with ADs 1441 (49.0) 7684 (52.3) 1 (Ref) 1 (Ref)
Monotherapy with AD 877 (29.8) 3646 (24.8) 0.77 (0.70–0.84) 0.78 (0.71–0.86)
No AD 566 (19.2) 3100 (21.1) 0.74 (0.66–0.84) 0.76 (0.68–0.86)
Self-harm and suicide
All cases
 Combination therapy with quetiapine 404 (7.1) 642 (2.2) 2.37 (2.07–2.71) 1.53 (1.31–1.79)
 Monotherapy with quetiapine 70 (1.2) 207 (0.7) 1.27 (0.96–1.67) 0.71 (0.52–0.99)
 Combination therapy with ADs 1848 (32.3) 7115 (24.9) 1 (Ref) 1 (Ref)
 Monotherapy with AD 2403 (42.1) 14,103 (49.4) 0.63 (0.59–0.68) 0.66 (0.61–0.71)
 No AD 989 (17.3) 6503 (22.8) 0.55 (0.50–0.60) 0.52 (0.47–0.58)
Incident  casesa
 Combination therapy with quetiapine 223 (5.7) 423 (2.2) 1.93 (1.62–2.30) 1.52 (1.26–1.84)
 Monotherapy with quetiapine 39 (1.0) 101 (0.5) 1.37 (0.94–2.00) 1.02 (0.68–1.53)
 Combination therapy with ADs 1310 (33.4) 4895 (25.0) 1 (Ref) 1 (Ref)
 Monotherapy with AD 1665 (42.5) 9670 (49.4) 0.62 (0.57–0.67) 0.64 (0.59–0.70)
 No AD 681 (17.4) 4501 (23.0) 0.53 (0.47–0.59) 0.52 (0.47–0.58)
Extrapyramidal disorders
Combination therapy with quetiapine 51 (9.8) 46 (1.8) 5.61 (3.53–8.90) 6.15 (3.57–10.58)
Monotherapy with quetiapine 16 (3.1) 8 (0.3) 9.23 (3.84–22.17) 13.51 (4.98–36.65)
Combination therapy with ADs 129 (24.7) 627 (24.0) 1 (Ref) 1 (Ref)
Monotherapy with AD 246 (47.0) 1342 (51.3) 0.88 (0.69–1.11) 1.05 (0.81–1.37)
No AD 81 (15.5) 592 (22.6) 0.66 (0.49–0.91) 0.70 (0.49–0.99)
Somnolence
Combination therapy with quetiapine 25 (4.6) 45 (1.6) 2.45 (1.45–4.13) 2.41 (1.42–4.11)
Monotherapy with quetiapine 5 (0.9) 15 (0.5) 1.48 (0.52–4.17) 1.52 (0.53–4.33)
Combination therapy with ADs 268 (49.1) 1387 (50.8) 1 (Ref) 1 (Ref)
Monotherapy with AD 153 (28.0) 680 (24.9) 0.85 (0.68–1.06) 0.86 (0.69–1.07)
No AD 95 (17.4) 603 (22.1) 0.69 (0.51–0.92) 0.70 (0.52–0.93)
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outcomes—as does, importantly, having psychiatric diag-
noses such as anxiety and depression [39, 40]. The relative 
risks for AMI and stroke were similar in the overall study 
population, although in the age-stratified analysis, the risk 
for stroke was higher for use of quetiapine in combination 
with antidepressants among patients aged ≥ 65 years. This 
is in line with an observational study showing an increased 
risk for stroke among elderly patients treated with quetiapine 
compared with non-users [41], and a study where atypical 
antipsychotic drugs were also associated with an increased 
risk of stroke, particularly in elderly patients and those with 
dementia [42]. However, the results from the present study 
should be interpreted with caution because the lower bound-
ary of the CI for this finding was very close to 1, few events 
were reported, and the aOR was not increased for patients 
aged ≥ 65 years receiving quetiapine as monotherapy. In 
addition, the fact that none of the other analyses showed 
any significant increases may indicate that this is not a major 
risk with quetiapine treatment in this population.
Table 3  Association between 
selected study outcomes and 
treatment with quetiapine or 
ADs at the time of an event, 
stratified by age
Adjusted ORs and their 95% CIs were estimated with conditional logistic regression models, including all 
prespecified covariates, using combination therapy with ADs as the reference category
AD antidepressant, AMI acute myocardial infarction, CI confidence interval, OR odds ratio, Ref reference
a Quetiapine exposure had to be collapsed due to a small number of events
b Excluding patients with a history of self-harm prior to the index date
Age 18–64 years Age ≥ 65 years
Adjusted OR (95% CI) Adjusted OR (95% CI)
All-cause mortality
Combination therapy with quetiapine 1.20 (0.87–1.66) 1.31 (1.09–1.58)
Monotherapy with quetiapine 1.17 (0.65–2.11) 1.37 (0.93–2.01)
Combination therapy with ADs 1 (Ref) 1 (Ref)
Monotherapy with AD 0.66 (0.58–0.75) 0.91 (0.87–0.96)
No medication 0.77 (0.66–0.90) 0.98 (0.92–1.05)
AMI
Monotherapy or combination therapy with  quetiapinea 0.64 (0.28–1.44) 1.28 (0.82–2.00)
Combination therapy with ADs 1 (Ref) 1 (Ref)
Monotherapy with AD 0.83 (0.65–1.08) 0.96 (0.84–1.09)
No AD 0.80 (0.59–1.08) 1.10 (0.93–1.32)
Stroke
Combination therapy with quetiapine 0.78 (0.39–1.56) 1.47 (1.01–2.12)
Monotherapy with quetiapine 1.56 (0.53–4.55) 0.98 (0.37–2.61)
Combination therapy with ADs 1 (Ref) 1 (Ref)
Monotherapy with AD 0.99 (0.79–1.24) 0.87 (0.78–0.96)
No AD 0.94 (0.72–1.23) 0.90 (0.78–1.04)
Diabetes mellitus
Monotherapy or combination therapy with  quetiapinea 1.01 (0.72–1.41) 0.46 (0.22–0.98)
Combination therapy with ADs 1 (Ref) 1 (Ref)
Monotherapy with AD 0.77 (0.68–0.87) 0.79 (0.68–0.93)
No AD 0.71 (0.61–0.83) 0.85 (0.69–1.04)
Self-harm and suicide
All cases
 Monotherapy or combination therapy with  quetiapinea 1.34 (1.15–1.56) 1.22 (0.71–2.08)
 Combination therapy with ADs 1 (Ref) 1 (Ref)
 Monotherapy with AD 0.66 (0.61–0.72) 0.65 (0.53–0.79)
 No AD 0.50 (0.45–0.56) 0.75 (0.58–0.99)
Incident  casesb
 Monotherapy or combination therapy with  quetiapinea 1.38 (1.15–1.66) 0.85 (0.48–1.52)
 Combination therapy with ADs 1 (Ref) 1 (Ref)
 Monotherapy with AD 0.61 (0.55–0.67) 0.59 (0.48–0.73)
 No AD 0.48 (0.43–0.54) 0.71 (0.53–0.94)
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4.4  Extrapyramidal Disorder and Somnolence
In accordance with the pharmacological profile of quetiapine 
[43], elevated risks for extrapyramidal disorders and som-
nolence were observed with quetiapine use compared with 
the use of combinations of antidepressants. The risk increase 
regarding somnolence was observed even though many anti-
depressants, most notably mirtazapine, are associated with 
an increased risk compared with placebo [44]. However, the 
inference drawn from these analyses may be limited due to 
the fact that AEs may not be consistently registered in the 
PDR, although, in the case of extrapyramidal disorders, the 
analyzed outcome also included prescriptions of biperiden 
and trihexyphenidyl.
4.5  Strengths and Limitations
Strengths of this study include the use of nationwide Swed-
ish registers as data sources, which in general have high 
quality and completeness [22, 24], and which provided an 
initial study population with sufficient power to perform 
nested case–control analyses while adjusting for several 
potential confounders. Because the controls were randomly 
sampled from the eligible controls in the study population, 
the sampling probability as a control was proportional to the 
amount of person-time that patient had spent at risk of dis-
ease, and since there was matching on time from inclusion 
into the study population until the outcome, the follow-up 
time was similar for cases and controls [45]. Although little 
precision is typically gained by selecting more than four 
controls to each case, there can be some gain and, espe-
cially for rare exposures, a higher number of controls also 
help to increase the chance of catching exposures to better 
estimate the true exposure among all the potential controls 
[45]. Accordingly, because we found that we could achieve 
a higher number of controls than four to nearly all cases, we 
chose to do so.
The method of comparing second-line users of quetiapine 
with patients with other second-line antidepressant treatment 
was intended to emulate the treatment setting in which que-
tiapine is likely to be prescribed, and also to create compari-
son groups, taking into account the inherent risks for several 
adverse outcomes associated with both psychiatric diagnoses 
and with antidepressant therapy in general [39, 40], risks 
that generally increase among difficult-to-treat patients [46].
Limitations of this study include the main indication for 
treatment not being available in the PDR; hence, the inclu-
sion of patients with non-psychiatric indications for anti-
depressant use, such as neuropathic pain, fibromyalgia, or 
premenstrual syndrome, could not be avoided. Reasons for 
drug switch or discontinuation were unknown, and could 
be due a number of reasons, such as poor response, adverse 
effects, poor adherence, remission, or interactions with other 
prescribed drugs, including non-psychiatric drugs. Drug 
dispensing information in the PDR was not available for 
treatments administered only during hospital admissions, 
and the NPR does not include visits or diagnoses from pri-
mary care, therefore this information was not available for 
adjustment in the study. Socioeconomic and smoking data 
were also unavailable, and such risk factors may have been 
unevenly distributed in the exposure groups. Considering 
the higher rate of substance-use disorders among patients 
with quetiapine, and the suspected channeling bias of quetia-
pine towards patients with greater psychiatric morbidity, it is 
likely that these factors could have affected the risks of mor-
tality, AMI, and stroke, especially among quetiapine users. 
Thus, residual confounding is likely to remain in the analy-
sis, suggested by the differing characteristics between patient 
groups. Extrapyramidal disorder and somnolence outcomes 
may have been underreported because the main underlying 
reason for the medical encounter (e.g. depressive episode) 
is most likely to be the one recorded as a diagnosis rather 
than an AE. Although the validity of recorded diagnoses in 
the NPR is generally high, no validations of any diagnoses 
were performed. In addition, hospitalizations for MDD were 
incorporated as measures for severity as there are no agreed-
upon constructs for assessment of severity of MDD.
Patients’ actual use of the filled prescriptions was 
unknown, but was likely to have been less than optimal, 
since high rates of non-adherence to antidepressant medi-
cation have been reported [47]. Finally, to ensure that the 
study was adequately powered, this study included patients 
using both the immediate-release (IR) and ER quetiapine 
formulations. The IR quetiapine formulation is indicated for 
schizophrenia and manic and depressive episodes of bipolar 
I disorder, and is more frequently prescribed, whereas the 
XR formulation is additionally indicated as add-on treatment 
for MDD [15]. Consequently, the patient populations and 
their associated comorbidities may have differed between 
the two formulations. However, results reported in the origi-
nal reports from analyses restricted to the use of the XR 
formulation were consistent with the results in the present 
study (data not shown). The proportion of cases and controls 
found to use quetiapine in monotherapy in the present study 
was comparable with what was found in a drug utilization 
study of quetiapine XR use for MDD across five European 
countries, including Sweden [48].
The results from this study are representative of the out-
patient population of antidepressant users, although not of 
inpatient users, in Sweden. Although the results may be 
generalizable to other patient populations prescribed antide-
pressants in other countries, they may vary due to differing 
treatment practices, reimbursement systems for medication 
costs, and organization of health care, and, more specifically, 
psychiatric care, in each country.
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5  Conclusions
The risk for self-harm and suicide was increased for mono-
therapy or combination therapy of quetiapine and antidepres-
sants in the 18–64 years age group only. This could possibly 
be explained by selective prescribing of these treatments to 
patients at high risk for these outcomes. When quetiapine 
was used in combination with antidepressants, a higher risk 
for stroke and all-cause mortality was found in the older 
age group (≥ 65 years), although the increased mortality 
did not remain when patients with Parkinson’s disease were 
excluded. No significant associations were found between 
quetiapine use (either as monotherapy or in combination) 
and AMI or diabetes.
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